PREFERRED SPECIALTY MANAGEMENT POLICY

POLICY: Idiopathic Pulmonary Fibrosis and Related Lung Disease – Pirfenidone Preferred Specialty Management Policy
- Esbriet® (pirfenidone film-coated tablets and capsules – Genentech, generic and branded generic tablets)

REVIEW DATE: 06/28/2023

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Pirfenidone, a pyridone, is indicated for the treatment of idiopathic pulmonary fibrosis.[1] Pirfenidone capsules are available in the 267 mg strength as brand and generic products. Pirfenidone film-coated tablets are available as a generic and a brand product in strengths of 267 mg and 801 mg; the 534 mg strength tablet is branded generic pirfenidone.

POLICY STATEMENT

This Preferred Specialty Management program has been developed to encourage the use of Preferred Products. For all medications (Preferred and Non-Preferred), the patient is required to meet the respective standard *Prior Authorization Policy* criteria. The patient is also required to try the Preferred Products. Requests for the Non-Preferred Products will also be reviewed using the exception criteria (below). All approvals for Preferred and Non-Preferred Products are provided for 1 year. If the patient meets the standard *Idiopathic Pulmonary Fibrosis and Related Lung Disease – Pirfenidone Prior Authorization Policy* criteria but has not tried the respective generic Preferred Product, approval for generic Preferred Products will be authorized.

Documentation: Documentation is required where noted in the criteria as **[documentation required]**. Documentation may include, but is not limited to, chart notes, prescription claims records, and/or other information.

Preferred Products: generic pirfenidone tablets (267 mg and 801 mg), generic pirfenidone capsules (267 mg)

Non-Preferred Products: Esbriet capsules (267 mg), Esbriet tablets (267 mg and 801 mg), branded generic pirfenidone 534 mg tablets

Idiopathic Pulmonary Fibrosis and Related Lung Disease – Pirfenidone non-preferred product(s) is(are) covered as medically necessary when the following non-preferred product exception criteria is(are) met. Any other exception is considered not medically necessary.

NON-PREFERRED PRODUCT EXCEPTION CRITERIA

Non-Preferred Products	Exception Criteria
Esbriet capsules (267 mg), Esbriet tablets (267 and 801 mg) and branded generic pirfenidone 534 mg tablets	**1.** Approve for 1 year if the patient meets both of the following (A and B): **A)** Patient meets the standard *Idiopathic Pulmonary Fibrosis and Related Lung Disease – Pirfenidone Prior Authorization Policy* criteria; AND **B)** Patient meets both of the following (i and ii): **i.** Patient has tried generic pirfenidone **[documentation required]**; AND **ii.** Patient has experienced inadequate efficacy or significant intolerance, according to the prescriber **[documentation required]**. **2.** For patients who meet the standard *Idiopathic Pulmonary Fibrosis and Related Lung Disease – Pirfenidone Prior Authorization Policy* criteria but have not tried generic pirfenidone, approve generic pirfenidone.

REFERENCES

1. Esbriet® capsules and film-coated tablets [prescribing information]. South San Francisco, CA: Genentech; February 2023.

HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	--	06/15/2022
Selected Revision	Esbriet capsules (267 mg) were added to the policy as a Non-Preferred medication. Criteria were added to approve for 1 year if the patient meets the standard *Idiopathic Pulmonary Fibrosis and Related Lung Disease – Pirfenidone Prior Authorization Policy* criteria and has tried generic pirfenidone tablets [documentation required] and the patient has experienced inadequate efficacy or significant intolerance, according to the prescriber [documentation required]. If the patient meets the standard *Idiopathic Pulmonary Fibrosis and Related Lung Disease – Pirfenidone Prior Authorization Policy* criteria but has not tried the respective generic Preferred Product, approval for a generic Preferred Product will be authorized.	06/29/2022
Selected Revision	Branded generic pirfenidone 534 mg tablets were added to the Policy as a Non-Preferred medication. Criteria for this product are the same as what currently is in place for the other Non-Preferred Products which is the standard multisource brand criteria.	09/28/2022
Selected Revision	Generic pirfenidone capsules (267 mg) were added as a Preferred Product. Criteria regarding Esbriet (brand name) capsules (a Non-Preferred Product) clarified the strength (267 mg) and was changed to allow approval if the patient has tried "generic pirfenidone" instead of specifying that the patient has tried "generic pirfenidone tablets"; similarly, automatic approvals were revised to state to approve "generic pirfenidone" instead of "generic pirfenidone tablets". Criteria for Esbriet tablets (267 and 801 mg) and branded generic pirfenidone 534 mg tablets (Non-Preferred Products) were changed from following the standard multisource brand criteria to the requirement that the patient has tried generic pirfenidone AND has experienced inadequate efficacy or significant intolerance, according to the prescriber; similarly, automatic approvals just state to approve "generic pirfenidone" instead of "generic pirfenidone tablets" The criteria were merged for all Non-Preferred Products as now it is identical.	01/25/2023
Annual Revision	No criteria changes.	06/28/2023